Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

In a major setback, Israel-based Pluristem Therapeutics Inc. (PSTI - Snapshot Report) recently announced that it has received notification from the US Food and Drug Administration (FDA), placing a clinical hold on the phase II intermittent claudication (IC) study (IND 15038).

The FDA’s decision was based on a serious allergic reaction in one of the patients which required subsequent hospitalization.

The patient was discharged the next day after the symptoms were managed.

Pluristem pointed out that the patient was suffering from multiple diseases which may have affected the severity of the allergic reaction.

However, the FDA will issue a letter to Pluristem within the next 30 days asking for further information.

Pluristem currently does not have any approved product/therapy. Hence, the clinical hold on the mid-stage trial significantly disappointed investors. The news led to a 14.4% decline in the stock price on Jun 4, 2013.

We expect investor focus in the near term to remain on further updates on the clinical hold.

We note that Pluristem develops placenta-based cell therapies in collaboration with companies like United Therapeutics (UTHR - Analyst Report) or through research and clinical institutions.

The cells from placenta are derived using the company’s proprietary PluriX therapy and are known as PLacental eXpanded (PLX) cells. Pluristem’s first candidate in development, PLX-PAD, is intended to treat peripheral artery disease (PAD).

Meanwhile, the company is also evaluating PLX-PAD for the treatment of critical limb ischemia and Buerger's disease.

Celgene Cellular Therapeutics, a wholly-owned subsidiary of Celgene Corporation (CELG - Analyst Report), is also conducting research on stem cells derived from the human placenta as well as from the umbilical cord for the treatment of different diseases.

Pluristem carries a Zacks Rank #4 (Sell). Right now, Anika Therapeutics, Inc. looks attractive with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 33.30 +8.22%
NOAH HOLDING NOAH 13.87 +4.36%
VALEO SA SPO VLEEY 67.91 +3.95%
GENTHERM INC THRM 36.12 +3.91%